Skip to main content Accessibility help

Hyperprolactinaemia: A guide for psychiatrists

  • Ovais Wadoo, Aadil Jan Shah, Rachael Hall and Yaasir Mamoojee

Medications prescribed by psychiatrists are known to elevate serum prolactin levels, but hyperprolactinaemia remains underrecognised, as the adverse effects of an elevated prolactin are mostly not visible. Hyperprolactinaemia can lead to adverse health outcomes, so clinicians need not only to be alert to its symptoms, but to manage the consequences as well. In this article we provide a brief overview of prolactin physiology, regulation and function. We list various factors that can lead to elevated serum prolactin. We discuss the interpretation of blood results and the management of psychotropic-induced hyperprolactinaemia. We include a flow diagram to assist clinicians in decision-making in the clinical management of hyperprolactinaemia.

Learning Objectives

• Understand prolactin physiology and regulation

• Understand hyperprolactinaemia and its causes

• Know the consequences of hyperprolactinaemia and appropriately manage it in clinical practice

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Hyperprolactinaemia: A guide for psychiatrists
      Available formats
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Hyperprolactinaemia: A guide for psychiatrists
      Available formats
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Hyperprolactinaemia: A guide for psychiatrists
      Available formats
Corresponding author
Correspondence Dr Ovais Wadoo, Tees, Esk & Wear Valleys NHS Foundation Trust, Roseberry Park Hospital, Marton Road, Middlesbrough TS4 3AF, UK. Email:
Hide All

Dr Wadoo and colleagues' e-learning module on this topic is available from the Royal College of Psychiatrists' CPD Online: click on The management of hyperprolactinemia in psychiatric practice or go to

Declaration of Interest


Hide All
Abel, A, Kimberly, IR, Robert, AV (2006) Incidence and clinical significance of elevated macroprolactin levels in patients with hyperprolactinemia. Endocrine Practice, 12: 275–80.
Bargiota, SI, Bonotis, KS, Messinis, IE, et al (2013) The effects of antipsychotics on prolactin levels and women's menstruation. Schizophrenia Research and Treatment, 24 Dec: doi 10.1155/2013/502697 [Epub].
Brugnoli, R, Novick, D, Maria Haro, J, et al (2012) Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study. BMC Psychiatry, 12: 83.
Busche, C, Yeomans, D, Floyd, T, et al (2008) Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. Journal of Psychopharmacology, 22: 5662.
Byerly, M, Suppes, T, Tran, QV, et al (2007) Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. Journal of Clinical Psychopharmacology, 27: 639–61.
Byerly, MJ, Marcus, RN, Tran, QV, et al (2009) Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophrenia Research, 107: 218–22.
Canadian Society of Clinical Chemists (1992) Canadian Society of Clinical Chemists position paper: standardization of selected polypeptide hormone measurements. Clinical Biochemistry, 25: 415–24.
Chang, SC, Chen, C-H, Lu, M-L (2008) Cabergoline-induced psychotic exacerbation in schizophrenic patients. General Hospital Psychiatry, 30: 378–80.
Coker, F, Taylor, D (2010) Antidepressant-induced hyperprolactinaemia incidence, mechanisms and management. CNS Drugs, 24: 563–74.
Corenblum, B, Pairaudeau, N, Shewchuk, AB (1976) Prolactin hypersecretion and short luteal phase defects. Obstetrics and Gynecology, 47: 486–8.
David, SR, Taylor, CC, Kinon, BJ, et al (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics, 22: 1085–96.
Dekkers, OM, Ehrenstein, V, Bengtsen, M, et al (2015) Breast cancer risk in hyperprolactinemia patients: a population-based cohort study and meta-analysis of the literature. European Journal of Endocrinology, 173: 269–73.
De Rivera, JL, Lal, S, Ettigi, P, et al (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clinical Endocrinology, 5: 273–85.
Di Somma, C, Colao, A, Di Sarno, A, et al (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. Journal of Clinical Endocrinology and Metabolism, 83: 807–13.
Fell, MJ, Neill, JC, Marshall, KM (2004) Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. European Neuropsychopharmacology, 14: 385–92.
Greenspan, SL, Neer, RM, Ridgway, EC, et al (1986) Osteoporosis in men with hypoprolactinemic hypogonadism. Annals of Internal Medicine, 104: 777–82.
Haddad, PM, Wieck, A (2004) Antipsychotic-induced hyperprolactinaemia mechanisms, clinical features and management. Drugs, 64: 2291–314.
Holt, RIG, Peveler, RC (2011) Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clinical Endocrinology, 74: 141–7.
Inder, WJ, Castle, D (2011) Antipsychotic-induced hyperprolactinaemia. Australian and New Zealand Journal of Psychiatry, 45: 830–7.
Kavanagh-Wright, L, Smith, TP, Gibney, J, et al (2009) Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clinical Endocrinology, 70: 599605.
Kelly, DL, Wehring, HJ, Earl, AK, et al (2013) Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry, 13: 214.
Kleinberg, DL, Noel, GL, Frantz, AG (1977) Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. New England Journal of Medicine, 296: 589600.
Klibanski, , Neer, RM, Beitins, IZ, et al (1980) Decreased bone density in hyperprolactinemic women. New England Journal of Medicine, 303: 1511–4.
Kotorki, P, Pelka, P, Leotsakou, C, et al (2010) Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole. Annals of General Psychiatry, 9 (suppl 1): S164.
La Torre, D, Alberto, F (2007) Pharmacological causes of hyperprolactinemia. Therapeutics and Clinical Risk Management, 3: 929–51.
Melmed, S, Casanueva, FF, Hoffman, AR, et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 96: 273–88.
Molitch, ME (2008) Drugs and prolactin. Pituitary, 11: 209–18.
National Institute for Health and Care Excellence (2014) Psychosis and Schizophrenia in Adults: Prevention and Management (Clinical Guideline CG178). NICE.
Perkins, DO (2004) Antipsychotic induced hyperprolactinemia: pathophysiology and clinical consequences. Advanced Studies in Medicine, 4(10F): S9826.
Sánchez-Eixerés, MR, Mauri, M, Alfayate, R, et al (2001) Prevalence of macroprolactin detected by Elecsys 2010. Hormone Research, 56: 8792.
Schlechte, J, Walkner, L, Kathol, M (1992) A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism, 75: 698703.
Schlechte, JA (2003) Prolactinoma. New England Journal of Medicine, 349: 2035–41.
Segal, S, Yaffe, H, Laufer, N, et al (1979) Male hyperprolactinemia: effects on fertility. Fertility and Sterility, 32: 556–61.
Shim, JC, Shin, JG, Kelly, DL, et al (2007) Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. American Journal of Psychiatry, 164: 1404–10.
Sobrinho, LG (1998) Emotional aspects of hyperprolactinemia. Psychotherapy and Psychosomatics, 67: 133–9.
Sonino, N, Tomba, E, Fava, GA (2007) Psychosocial approach to endocrine disease. Advances in Psychosomatic Medicine, 28: 2133.
Taylor, D, Paton, C, Kapur, S (2015) The Maudsley Prescribing Guidelines in Psychiatry (12th edn). Wiley-Blackwell.
Tworoger, SS, Eliassen, AH, Sluss, P, et al (2007) A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. Journal of Clinical Oncology, 25: 1482–8.
Tworoger, SS, Eliassen, AH, Zhang, X, et al (2013) A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Research, 73: 4810–9.
Tyson, JE, Hwang, P, Guyda, H, et al (1972) Studies of prolactin secretion in human pregnancy. American Journal of Obstetrics & Gynecology, 113(1): 1420.
Walters, J, Jones, I (2008) Clinical questions and uncertainty: prolactin measurement in patients with schizophrenia and bipolar disorder. Journal of Psychopharmacology, 22 (suppl 2): 82–9.
Wass, J, Shalet, S, Gale, E, et al (2011) Oxford Textbook of Endocrinology and Diabetes (2nd edn). Oxford University Press.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Advances
  • ISSN: 2056-4678
  • EISSN: 2056-4686
  • URL: /core/journals/bjpsych-advances
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
Type Description Title
Supplementary materials

Wadoo et al. supplementary material



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Hyperprolactinaemia: A guide for psychiatrists

  • Ovais Wadoo, Aadil Jan Shah, Rachael Hall and Yaasir Mamoojee
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *